Novartis Boosts Oncology With GSK Assets; Goal Is “Preferential Access”
This article was originally published in The Pink Sheet Daily
Executive Summary
Surprise acquisition of GSK’s marketed oncology products accompanies joint venture on OTC/consumer health; less surprising deals include divesting its animal health business to Lilly and its vaccines business (but not flu vaccines) to GSK.